Biobanking Market Share

  • Report ID: 4602
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Biobanking Market Regional Analysis:

North American Market Insights

North America region is likely to hold over 40.8% market share by 2035, fueled by the rising adoption of advanced technology and growing awareness regarding biobanking. For instance, the 16 largest pharmaceutical firms in the United States invested about USD 140 billion in research and development in 2021, which represents a 43% hike from 2016. Additionally, the surge in stem cell practices in the region to develop solutions for various diseases backed by the ongoing development via stem cell technology in regenerative medicines is further projected to expand the market size during the forecast period. Stem cell technology has become the most important treatment method for multiple diseases such as cancer, rare genetic diseases, diabetes, Alzheimer’s, and others. In the United States, approximately 30 million people suffer from diabetes. However, in 2018, around 25 million people were diagnosed with diabetes in a similar region.

Biobanking Market Share

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of biobanking is evaluated at USD 28.74 billion.

The global biobanking market size was worth over USD 26.7 billion in 2025 and is poised to grow at a CAGR of around 8.5%, reaching USD 60.37 billion revenue by 2035.

North America biobanking market will secure around 40.8% share by 2035, driven by the rising adoption of advanced technology and growing awareness regarding biobanking.

Key players in the market include UK Biobank Limited, Thermo Fisher Scientific Holdings, Inc., Tecan Trading AG, Hamilton Bonaduz AG, Bay Biosciences LLC., ISENET USA LLC, ASKION GmbH, Promega Corporation, VWR International, LLC., Merck KGaA.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos